Core Viewpoint - The performance of Jianxin Inherent Power A fund has significantly lagged behind the market, with a year-to-date net asset value decline of 12.6% compared to a 4.68% increase in the CSI 300 index, indicating poor investment decisions and high turnover rates [1][7]. Fund Performance - Jianxin Inherent Power A has experienced a net asset value decline of 12.6% as of July 22, 2025, underperforming its benchmark by approximately 16.4 percentage points [7]. - The fund's performance has been volatile, with a decline of over 40% since the current fund manager, Sun Sheng, took over in October 2021 [5]. - Historical performance shows the fund had losses of 29.79% in 2022 and 21.94% in 2023, with a slight gain of 17.05% in 2024 [6]. Investment Strategy - The fund has a high turnover rate, with stock turnover rates of approximately 851.64%, 1140.08%, and 619.19% for the years 2022, 2023, and 2024, respectively, indicating aggressive trading strategies [8]. - As of the end of Q2 2025, the fund's stock holdings accounted for 85.72% of total assets, with the top ten holdings representing 54.94% of net asset value [8]. - The fund's investment style is aggressive, focusing heavily on the domestic computing power chain sector, which has underperformed in the second quarter of 2025 [9]. Manager Overview - Sun Sheng has managed Jianxin Inherent Power A since October 2021 and oversees a total of four funds, all of which have shown declines in net asset value this year [2][11]. - The overlapping stock holdings among the funds managed by Sun Sheng have contributed to the overall underperformance, with significant commonality in top holdings [12].

Core Insights - The A-share market in the first half of 2025 exhibited a distinct structural trend, with pharmaceutical and biotechnology-themed funds dominating performance rankings [1] - Over 120 funds were liquidated during this period, indicating significant market shifts [1] Performance Summary Top Performing Funds - The top ten stock funds saw significant returns, with the leading fund, Huaan Pharmaceutical Bio A, achieving a return of 66.44% [2] - Other notable performers included Jiashi Huron Selected A (60.26%) and Ping An Pharmaceutical Selected A (58.80%) [2] - The average return of the top ten funds was driven primarily by smaller, actively managed funds, highlighting their flexibility in capturing rapid market movements [5] Underperforming Funds - The worst-performing funds were led by Jianxin China Manufacturing 2025 A, which recorded a decline of 14.68% [4] - Other funds in the bottom tier included Huaxia Advantage Selected and Great Wall Quantitative Selected A, both with declines exceeding 12% [4] - The coal and photovoltaic sectors faced significant downward pressure, with several funds in these categories showing substantial losses [4] Sector Analysis Pharmaceutical and Biotechnology - The pharmaceutical and biotechnology sectors have seen a resurgence after a prolonged adjustment period, driven by improved valuations and supportive policies [5] - The global and domestic biotech investment climate is recovering, contributing to the strong performance of related funds [5] Coal and Photovoltaic Industries - The coal industry is experiencing a shift in supply-demand dynamics, leading to downward pressure on valuations due to economic restructuring and accelerated energy transitions [5] - The photovoltaic sector is facing intensified competition and concerns over overcapacity, impacting short-term profitability and stock performance [5] Market Outlook - The A-share market is expected to show a trend of gradual upward movement in the second half of 2025, supported by increased participation from public funds and favorable policies [6] - However, significant differentiation among sectors may lead to rebalancing pressures, particularly in pharmaceuticals and biotechnology [6] - Investors are advised to analyze macroeconomic trends and industry policies to identify opportunities amidst market volatility [6]

Group 1 - The core viewpoint of the article highlights the strong performance of actively managed equity funds, particularly those focused on the Beijing Stock Exchange and the pharmaceutical sector, with the top-performing fund achieving a return of 82.45% in the first half of 2025 [1][7]. - The top-performing funds include the CITIC Securities Beijing Stock Exchange Selected Two-Year Open A Fund, which is the only fund to exceed an 80% return, and other notable funds such as Great Wall Pharmaceutical Industry Selected A and Bank of China Hong Kong Stock Connect Pharmaceutical A, both exceeding 70% returns [2][7]. - The overall performance of the A-share and Hong Kong stock markets was positive, with major indices showing gains, particularly the North Exchange 50 Index, which rose by 39.45% [5][6]. Group 2 - Looking ahead to the second half of 2025, several fund companies express optimism about investment opportunities in the A-share market due to historically low valuation levels and supportive fiscal and monetary policies [3][10]. - Fund managers are particularly focused on sectors such as technology, innovative pharmaceuticals, and new consumption, anticipating structural opportunities in these areas [11][12]. - The Hong Kong market is expected to attract more investment due to the internationalization of the RMB and the listing of quality A-shares and overseas Chinese assets, which enhances its appeal [10]. Group 3 - Despite the overall positive outlook, some actively managed equity funds have underperformed, with the Qianhai Kaiyuan Artificial Intelligence A Fund showing a decline of 20.57%, marking it as the worst performer [9]. - Fund managers emphasize the importance of identifying structural opportunities in the market, particularly in sectors like AI, semiconductors, and military industry, as well as in cyclical industries that have seen significant price declines [11][12].